AD patients (n=21) and healthy age-matched control subjects (n=16) were supplemented with either Macushield™ (10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin) or placebo (sunflower oil) for six months.
The MRM-MS method determined serum POVPC sensitively (from 10 µl serum) and reproducibly (CV=7.9%). At baseline, AD subjects had higher serum POVPC compared to age-matched controls, (p=0.017) and cognitive function was correlated inversely with POVPC (r=−0.37; p=0.04). After six months of carotenoid intervention, serum POVPC was not different in AD patients compared to healthy controls. However, POVPC was significantly higher in control subjects after six months of carotenoid intervention compared to their baseline (p=0.03). Serum IsoP concentration was unrelated to disease or supplementation. Serum FRAP was significantly lower in AD than healthy controls but was unchanged by carotenoid intervention (p=0.003).
In conclusion, serum POVPC is higher in AD patients compared to control subjects, is not reduced by carotenoid supplementation and correlates with cognitive function.
|Number of pages||9|
|Journal||Free Radical Biology and Medicine|
|Early online date||14 Mar 2017|
|Publication status||Published - Jul 2017|
Bibliographical note© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Funding: BBSRC; Kidney Research Foundation; ARUK; Howard Foundation; and Aston Research Centre for Healthy Ageing
- oxidative stress
- lipid peroxidation
- mass spectrometry
- cognitive function
FingerprintDive into the research topics of 'Phospholipid oxidation and carotenoid supplementation in Alzheimer’s disease patients'. Together they form a unique fingerprint.
Ademowo, S. (Creator), Dias, I. (Creator), Milic, I. (Creator), Devitt, A. (Creator), Moran, R. (Creator), Mulcahy, R. (Creator), Howard, A. (Creator), Nolan, J. (Creator) & Griffiths, H. (Creator), Aston Data Explorer, 16 Mar 2017